Agilon Health (NYSE:AGL – Get Free Report) had its price objective upped by equities researchers at Robert W. Baird from $20.00 to $35.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential downside of 35.01% from the company’s previous close.
Other equities analysts have also recently issued research reports about the company. Barclays dropped their price target on Agilon Health from $25.00 to $12.50 and set an “underweight” rating on the stock in a research report on Friday, February 27th. Wells Fargo & Company boosted their price target on Agilon Health from $25.00 to $37.50 and gave the company an “overweight” rating in a research report on Friday, February 27th. Deutsche Bank Aktiengesellschaft upgraded Agilon Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $33.00 to $49.00 in a research report on Thursday. JPMorgan Chase & Co. cut Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 price target on the stock. in a research report on Monday, May 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $37.93.
Check Out Our Latest Report on Agilon Health
Agilon Health Stock Down 11.2%
Agilon Health (NYSE:AGL – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.76. The firm had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.38 billion. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%. Analysts anticipate that Agilon Health will post -6.36 EPS for the current year.
Hedge Funds Weigh In On Agilon Health
Several institutional investors and hedge funds have recently added to or reduced their stakes in AGL. Goldman Sachs Group Inc. increased its position in Agilon Health by 196.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock worth $13,812,000 after purchasing an additional 13,283,930 shares during the period. AQR Capital Management LLC grew its holdings in shares of Agilon Health by 1,346.6% in the 4th quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after acquiring an additional 9,505,837 shares during the period. CenterBook Partners LP grew its holdings in shares of Agilon Health by 492.4% in the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after acquiring an additional 9,499,012 shares during the period. North Peak Capital Management LLC grew its holdings in shares of Agilon Health by 10.8% in the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock worth $26,267,000 after acquiring an additional 3,715,460 shares during the period. Finally, Voleon Capital Management LP grew its holdings in shares of Agilon Health by 5,519.2% in the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company’s stock worth $2,823,000 after acquiring an additional 2,692,259 shares during the period.
Key Agilon Health News
Here are the key news stories impacting Agilon Health this week:
- Positive Sentiment: Agilon Health reported Q1 2026 earnings of $1.80 per share, well above Wall Street estimates, and revenue also topped expectations, helping fuel a major rally in the stock. Agilon Health Operational Initiatives Begin Showing Results
- Positive Sentiment: The company raised its full-year 2026 guidance, with revenue outlook above consensus, signaling that recent operational initiatives may be starting to pay off. Agilon Health Operational Initiatives Begin Showing Results
- Positive Sentiment: Several coverage pieces highlighted the strong quarter and the stock’s big move, reinforcing investor optimism around the turnaround story. agilon health (NYSE:AGL) Reports Strong Q1 CY2026, Stock Jumps 27.9%
- Neutral Sentiment: Jefferies upgraded Agilon Health, adding to the positive sentiment, though another firm, Robert W. Baird, raised its price target while keeping a neutral view on the stock. Jefferies upgrades Agilon Health (AGL)
- Neutral Sentiment: Recent earnings-call transcripts and analysis focused on the company’s performance details and management commentary, but did not add a materially new catalyst beyond the earnings beat and guidance increase. Agilon Health, Inc. (NYSE:AGL) Q1 2026 Earnings Call Transcript
- Negative Sentiment: While not a fresh negative catalyst, prior reporting noted Agilon had been under pressure in 2025 due to weak financial performance and a suspended guidance outlook, which helps explain why the recent rebound is being viewed as a turnaround. Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
About Agilon Health
Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.
Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.
Featured Articles
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
